NEJM: Safety and effectiveness of single-dose Ad26.COV2.S vaccine

Ad26.
COV2.
S vaccine is a recombinant, non-replicating human type 26 adenovirus vector, which encodes the full-length spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with a stable conformation before fusion
.

Recently, a research article was published in the top medical journal NEJM.
In this double-blind, placebo-controlled phase 3 trial, researchers randomly assigned adult participants to receive a single dose of Ad26.
COV2 at a ratio of 1:1.
S (5×1010 virus particles) or placebo
.

The primary endpoint of the study is the vaccine's efficacy against moderate-to-severe-critical coronavirus disease (Covid-19).
Participants who tested negative for SARS in the eligible population should be at least 14 days and at least 28 days after administration Onset
.

The eligible population included 19,630 SARS-CoV-2 negative participants who received Ad26.
COV2.
S and 19,691 placebo participants
.

It can be seen that a single dose of Ad26.
COV2.
S can prevent symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection , and is effective for critical illnesses, including hospitalization and death
.